Mawi DNA Technologies has signed a distribution agreement with Benta Group, a leader in the healthcare industry to deliver Mawi’s iSWAB biosampling technologies to the Middle East, Africa and Eastern Europe.
According to Bernard Tannoury, Chairman and CEO of Benta, the Group has partnered with Mawi because of the latter’s extensive experience in genomics and proteomics as well as its success in re-inventing biosampling.
We are excited about partnering with Benta, which will facilitate Mawi’s access to new markets and strengthen our presence in others” says Dr. Bassam El-Fahmawi, President & CTO of Mawi DNA Technologies.
Benta Group will be an authorized agent and distributor for Mawi products in the following countries Bahrain, Jordan, Kuwait, Oman, Iraq, Iran, Lebanon, Libya, Egypt, Morocco, Tunisia, Algeria, Nigeria, Congo, Angola, Equatorial Guinea, Ghana, Soudan, South Africa, Slovenia, Croatia, Bosnia, Serbia, Macedonia, Lithuania, Czech Republic and Russia.
About Benta Group:
Benta Group is a leader in the healthcare industry that responds to the market’s growing need for healthcare services, pharmaceutical products, medical devices, medical equipment and medical research.
Benta Group is present in more than 30 countries mainly in Lebanon, GCC countries, Egypt, France and the CIS market. For more information about Benta Group, please visit www.benta.com.lb
About Mawi DNA Technologies:
Mawi DNA Technologies was founded in 2013 and has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. The company’s flagship product iSWAB-DNA has gained significant market traction due to its ability to be utilized for animals and all human population segments from infants to elderly, robust DNA yield, and low bacterial DNA content. Mawi DNA Technologies has established relationships with well known children’s hospitals for neonatal screening, and has set up an extensive network of international distributors to market and sell iSWAB products globally. For more information, please visit our website at https://2pointdemos.com/mawi/v2.
Candida Data Using iSWAB In Response to New Infectious Diseases...
A deadly fungal infection, Candida Auris, is becoming a serious threat. This drug-resistant strain is deadly for those with weakened immune systems and is spreading at an alarming rate. The READ MORE
Top Reasons to Ditch Your Current VTM. Upgrade your Viral…...
Mawi DNA has developed iSWAB-RC-EL, an FDA approved sample collection device for transport and storage of samples suspected of containing an infectious disease*. Why iSWAB-RC-EL is the superior op...
READ MOREMawi DNA Announces Dr. Bouzyk as New Board Member!...
It is with great delight and excitement that we announce that Dr. READ MORE